Table 3.
Results from current studies of EGFR-TKI efficacy on ADSC
| Study | No. of patients | Ethnicity | Stage | Gender | Smoking status | EGFR activating mutation | Type of TKI | DCR (%) | PFS (m) | OS (m) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I-IIIA | ≥ IIIB | Male | Female | No | Yes | Positive | Negative | |||||||
| Song et al., 2013 [17] | 49 | Asia | N/A | 53.1% (26/49) | 46.9% (23/49) | 26.5% (13/49) | 73.4% (36/49) | 33.30% (7/21) | 66.7% (14/21) | Gefitinib/ Erotinib | 65.3% (32/49) | 4.3 (2.1 for EGFR-; 8.7 for EGFR+) | 17.6 | |
| Fan et al., 2017 [30] | 27 | Asia | 85.2% (23/27) | 14.8% (4/27) | 40.7% (11/27) | 59.3% (16/27) | 74.1% (20/27) | 25.9% (7/27) | 100% (27/27) | 0% (0/27) | N/A | 74.1% (20/27) | 15 | 39 |
| Zhang et al., 2018 [28] | 148 | Asia | 100% (148/148) | 0% (0/148) | 70.7% (102/148) | 29.3% (46/148) | 42.6% (63/148) | 57.4% (85/148) | 20.2% (30/148) | 79.8% (118/148) | Gefitinib/ Erotinib | 76.7% (23/30) | N/A | 43 |
DCR Disease control rate, PFS Progression free survival, OS Overall survival, N/A Not applicable, TKI Tyrosine kinase inhibitor, EGFR- EGFR activating mutation negative, EGFR+ EGFR activating mutation positive